- Home
- DMLP vs DVAX Comparison
DMLP vs DVAX Comparison
Compare DMLP & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- DVAX
- Stock Information
- Founded
- DMLP 2003
- DVAX 1996
- Country
- DMLP United States
- DVAX United States
- Employees
- DMLP N/A
- DVAX N/A
- Industry
- DMLP Oil & Gas Production
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- DVAX Health Care
- Exchange
- DMLP Nasdaq
- DVAX Nasdaq
- Market Cap
- DMLP 1.1B
- DVAX 1.2B
- IPO Year
- DMLP N/A
- DVAX 2004
- Fundamental
- Price
- DMLP $24.35
- DVAX $10.05
- Analyst Decision
- DMLP
- DVAX Buy
- Analyst Count
- DMLP 0
- DVAX 4
- Target Price
- DMLP N/A
- DVAX $26.50
- AVG Volume (30 Days)
- DMLP 90.1K
- DVAX 1.3M
- Earning Date
- DMLP 11-07-2025
- DVAX 11-06-2025
- Dividend Yield
- DMLP 13.51%
- DVAX N/A
- EPS Growth
- DMLP N/A
- DVAX N/A
- EPS
- DMLP 1.71
- DVAX N/A
- Revenue
- DMLP $161,859,000.00
- DVAX $316,268,000.00
- Revenue This Year
- DMLP N/A
- DVAX $23.23
- Revenue Next Year
- DMLP N/A
- DVAX $16.57
- P/E Ratio
- DMLP $13.96
- DVAX N/A
- Revenue Growth
- DMLP 4.04
- DVAX 26.66
- 52 Week Low
- DMLP $23.63
- DVAX $9.20
- 52 Week High
- DMLP $34.88
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- DMLP 42.94
- DVAX 50.65
- Support Level
- DMLP $23.63
- DVAX $9.71
- Resistance Level
- DMLP $24.40
- DVAX $10.12
- Average True Range (ATR)
- DMLP 0.50
- DVAX 0.23
- MACD
- DMLP -0.09
- DVAX 0.01
- Stochastic Oscillator
- DMLP 31.07
- DVAX 52.31
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.